Obs and gyn Flashcards
Post-partum haemorrhage
Postpartum haemorrhage (PPH) is defined as blood loss of > 500mls and may be primary or secondary
Primary PPH
occurs within 24 hours
affects around 5-7% of deliveries
most common cause of PPH is uterine atony (90% of cases). Other causes include genital trauma and clotting factors
Risk factors for primary PPH include*: previous PPH prolonged labour pre-eclampsia increased maternal age polyhydramnios emergency Caesarean section placenta praevia, placenta accreta macrosomia ritodrine (a beta-2 adrenergic receptor agonist used for tocolysis)
Management
ABC including two peripheral cannulae, 14 gauge
IV syntocinon (oxytocin) 10 units or IV ergometrine 500 micrograms
IM carboprost
if medical options failure to control the bleeding then surgical options will need to be urgently considered
the RCOG state that the intrauterine balloon tamponade is an appropriate first-line ‘surgical’ intervention for most women where uterine atony is the only or main cause of haemorrhage
other options include: B-Lynch suture, ligation of the uterine arteries or internal iliac arteries
if severe, uncontrolled haemorrhage then a hysterectomy is sometimes performed as a life-saving procedure
Secondary PPH
occurs between 24 hours - 12 weeks**
due to retained placental tissue or endometritis
*the effect of parity on the risk of PPH is complicated. It was previously though multiparity was a risk factor but more modern studies suggest nulliparity is actually a risk factor
**previously the definition of secondary PPH was 24 hours - 6 weeks. Please see the RCOG guidelines for more details
Infertility
Infertility affects around 1 in 7 couples. Around 84% of couples who have regular sex will conceive within 1 year, and 92% within 2 years
Causes male factor 30% unexplained 20% ovulation failure 20% tubal damage 15% other causes 15%
Basic investigations
semen analysis
serum progesterone 7 days prior to expected next period. For a typical 28 day cycle, this is done on day 21.
Interpretation of serum progestogen
Level Interpretation
< 16 nmol/l Repeat, if consistently low refer to specialist
16 - 30 nmol/l Repeat
> 30 nmol/l Indicates ovulation
Key counselling points folic acid aim for BMI 20-25 advise regular sexual intercourse every 2 to 3 days smoking/drinking advice
Gravidity
number of times that a woman has been pregnant.
Parity
number of times that she has given birth to a fetus with a gestational age of 24 weeks or more, regardless of whether the child was born alive or was stillborn.
Hyperemesis gravidarum
It occurs in around 1% of pregnancies and is thought to be related to raised beta hCG levels. Hyperemesis gravidarum is most common between 8 and 12 weeks but may persist up to 20 weeks*.
Associations multiple pregnancies trophoblastic disease hyperthyroidism nulliparity obesity
NICE Clinical Knowledges Summaries recommend considering admission in the following situations:
Continued nausea and vomiting and is unable to keep down liquids or oral antiemetics
Continued nausea and vomiting with ketonuria and/or weight loss (greater than 5% of body weight), despite treatment with oral antiemetics
A confirmed or suspected comorbidity (for example she is unable to tolerate oral antibiotics for a urinary tract infection)
Hyperemesis gravidarum diagnostic criteria
- 5% pregnancy weight loss
- dehydration
- electrolyte imbalance
Management of hyperemesis gravidarum
- Antihistamines (promethazine or cyclizine)
- Ondansetron/metoclopromide
- Ginger/p6 acupressure
- Admission may be needed for IV hydration
Antenatal care: timetable
10 antenatal visits in the first pregnancy if uncomplicated
7 antenatal visits in subsequent pregnancies if uncomplicated
women do not need to be seen by a consultant if the pregnancy is uncomplicated
8 - 12 weeks (ideally < 10 weeks)
Booking visit
general information e.g. diet, alcohol, smoking, folic acid, vitamin D, antenatal classes
BP, urine dipstick, check BMI
Booking bloods/urine
FBC, blood group, rhesus status, red cell alloantibodies, haemoglobinopathies
hepatitis B, syphilis
HIV test is offered to all women
urine culture to detect asymptomatic bacteriuria
10 - 13+6 weeks
Early scan to confirm dates, exclude multiple pregnancy
11 - 13+6 weeks
Down’s syndrome screening including nuchal scan
16 weeks
Information on the anomaly and the blood results. If Hb < 11 g/dl consider iron
Routine care: BP and urine dipstick
18 - 20+6 weeks
Anomaly scan
25 weeks (only if primip)
Routine care: BP, urine dipstick, symphysis-fundal height (SFH)
28 weeks
Routine care: BP, urine dipstick, SFH
Second screen for anaemia and atypical red cell alloantibodies. If Hb < 10.5 g/dl consider iron
First dose of anti-D prophylaxis to rhesus negative women
31 weeks (only if primip)
Routine care as above
34 weeks
Routine care as above
Second dose of anti-D prophylaxis to rhesus negative women*
Information on labour and birth plan
36 weeks
Routine care as above
Check presentation - offer external cephalic version if indicated
Information on breast feeding, vitamin K, ‘baby-blues’
38 weeks
Routine care as above
40 weeks (only if primip)
Routine care as above
Discussion about options for prolonged pregnancy
41 weeks
Routine care as above
Discuss labour plans and possibility of induction
Oligohydraminos
abnormally low volume of amniotic fluid
amniotic fluid is mainly derived from foetal urine
premature rupture of membranes fetal renal problems e.g. renal agenesis intrauterine growth restriction post-term gestation pre-eclampsia
Post-partum contraception
- women require contraception after 21 days post-partum
Progesterone only pill post-partum
POP can be started at any point postpartum
after day 21 additional contraception needed for first 2 days
small amount of progesterone enters breastmilk - but not harmful
COCP postpartum
- absolute contraindication UKMEC 4 if breastfeeding <6 weeks postpartum
- UKMEC 2 - if breastfeeding 6 weeks - 6 months
- Do not use in first 21 days due to venous thromboembolism risk
- after day 21 additional contraception should be used for the first 7 days
- COCP may reduce breast milk production in lactating women
Intrauterine device postpartum
- can be inserted within 48 hours of childbirth or after 4 weeks
Lactational amenorrhea method (LAM) for contraception
98% effective providing woman is fully breastfeeding (no supplementary feeds), amenorrheic, and less than 6 months postpartum
What is the recommended time inter to wait between pregnancies
Less than 12 months between childbirth and conceiving is associated with increased risk of preterm birth, low birth weight, and small for gestational age babies
Ectopic pregnancy
Pregnancy outside of the uterine cavity
Risk factors of ectopic pregnancy
- Smoking
- History PID
- In-vitro fertilisation
- Gynecologic surgery
- Current IUD
- Tubal Ligation
- Previous ectopic pregnancy
DIagnosis of ectopic pregnancy
- Varies based on health
1. If hemodynamically unstable - SURGERY
- Haemodynamically stable (vital signs normal) - no hypertension or tachycardia
A. Serial HCG testing (levels should double every 2 days in a normal early pregnancy)
B. TV USS Intrauterine pregnancy (visible by weeks 5-6) and excess fluid
Conservative management of ectopic pregnancy
Indicated if:
- Hemodynamically stable
- Diagnosed early
- HCG declining
Perform serial HCG measurements and no additional tings
Medical management of ectopic pregnancy
Methotrexate
Surgical management of ectopic pregnancy
Salpingotomy
= the creation of an opening into the fallopian tube, but the tube itself is not removed in this procedure
Salpingectomy - which the affected Fallopian tube is removed,
Emergency contraception
- Levonorgestrel
- Ulipristal
- Copper IUD
Levonorgestrel
mode of action not fully understood - acts both to stop ovulation and inhibit implantation
should be taken as soon as possible - efficacy decreases with time
must be taken within 72 hours of unprotected sexual intercourse (UPSI)*
single dose of levonorgestrel 1.5mg (a progesterone)
the dose should be doubled for those with a BMI >26 or weight over 70kg
84% effective is used within 72 hours of UPSI
levonorgestrel is safe and well-tolerated. Disturbance of the current menstrual cycle is seen in a significant minority of women. Vomiting occurs in around 1%
if vomiting occurs within 3 hours then the dose should be repeated
can be used more than once in a menstrual cycle if clinically indicated
hormonal contraception can be started immediately after using levornogestrel (Levonelle) for emergency contraception
Ulipristal
a selective progesterone receptor modulator currently marketed as EllaOne. The primary mode of action is thought to be inhibition of ovulation
30mg oral dose taken as soon as possible, no later than 120 hours after intercourse
concomitant use with levonorgestrel is not recommended
Ulipristal may reduce the effectiveness of hormonal contraception. Contraception with the pill, patch or ring should be started, or restarted, 5 days after having ulipristal. Barrier methods should be used during this period
caution should be exercised in patients with severe asthma
repeated dosing within the same menstrual cycle was previously not recommended - however, this has now changed and ulipristal can be used more than once in the same cycle
breastfeeding should be delayed for one week after taking ulipristal. There are no such restrictions on the use of levonorgestrel
Intrauterine device (IUD)
a copper IUD is the most effective method of emergency contraception and should be offered to all women if they meet the criteria
if the criteria for insertion of a copper IUD are not met or is not acceptable to the woman, oral emergency contraception should be considered
in practice the vast majority of women choose oral emergency contraception, but it is important to offer the choice to all women given how effective copper IUDs are
must be inserted within 5 days of UPSI, or
if a woman presents after more than 5 days then an IUD may be fitted up to 5 days after the likely ovulation date
may inhibit fertilisation or implantation
prophylactic antibiotics may be given if the patient is considered to be at high-risk of sexually transmitted infection
is 99% effective regardless of where it is used in the cycle
may be left in-situ to provide long-term contraception. If the client wishes for the IUD to be removed it should be at least kept in until the next period
Placenta accreta
Placenta accreta describes the attachment of the placenta to the myometrium, due to a defective decidua basalis. As the placenta does not properly separate during labour there is a risk of post-partum haemorrhage.
Risk factors
previous caesarean section
placenta praevia
Strictly speaking, there are 3 different types of placenta accreta, depending on the degree of invasion although this is quite small print:
accreta: chorionic villi attach to the myometrium, rather than being restricted within the decidua basalis
increta: chorionic villi invade into the myometrium
percreta: chorionic villi invade through the perimetrium
Amenorrhoea
primary: defined as the failure to establish menstruation by 15 years of age in girls with normal secondary sexual characteristics (such as breast development), or by 13 years of age in girls with no secondary sexual characteristics
secondary: cessation of menstruation for 3-6 months in women with previously normal and regular menses, or 6-12 months in women with previous oligomenorrhoea
Primary amenorrhea
gonadal dysgenesis (e.g. Turner’s syndrome) - the most common causes
testicular feminisation
congenital malformations of the genital tract
functional hypothalamic amenorrhoea (e.g. secondary to anorexia)
congenital adrenal hyperplasia
imperforate hymen
Secondary amenorrhoea (after excluding pregnancy)
hypothalamic amenorrhoea (e.g. secondary stress, excessive exercise)
polycystic ovarian syndrome (PCOS)
hyperprolactinaemia
premature ovarian failure
thyrotoxicosis*
Sheehan’s syndrome
Asherman’s syndrome (intrauterine adhesions)
Termination of pregnancy
Key points
two registered medical practitioners must sign a legal document (in an emergency only one is needed)
only a registered medical practitioner can perform an abortion, which must be in a NHS hospital or licensed premise
The method used to terminate pregnancy depend upon gestation
less than 9 weeks: mifepristone (an anti-progestogen, often referred to as RU486) followed 48 hours later by prostaglandins to stimulate uterine contractions
less than 13 weeks: surgical dilation and suction of uterine contents
more than 15 weeks: surgical dilation and evacuation of uterine contents or late medical abortion (induces ‘mini-labour’)
1967 Abortion Act
Subject to the provisions of this section, a person shall not be guilty of an offence under the law relating to abortion when a pregnancy is terminated by a registered medical practitioner if two registered medical practitioners are of the opinion, formed in good faith
that the pregnancy has not exceeded its 24th week and that the continuance of the pregnancy would involve risk, greater than if the pregnancy were terminated, of injury to the physical or mental health of the pregnant woman or any existing children of her family; or
that the termination is necessary to prevent grave permanent injury to the physical or mental health of the pregnant woman; or
that the continuance of the pregnancy would involve risk to the life of the pregnant woman, greater than if the pregnancy were terminated; or
that there is a substantial risk that if the child were born it would suffer from such physical or mental abnormalities as to be seriously handicapped.
Medical termination of pregnancy
Oral mifepristone, followed by vaginal misoprostol.
Mifepristone is a progestogen antagonist that is used to ripen the cervix for medical termination of pregnancy and sensitise the myometrium to prostaglandin analogues. Misoprostol is a uterotonic prostaglandin analogue that initiates expulsion of pregnancy tissue, given 48 hours after mifepristone. Misoprostol may have to be given multiple times to ensure adequate expulsion of pregnancy tissue from the uterus. Mifepristone is only licensed for oral use in medical termination of pregnancy, while misoprostol may be given orally, sublingually, or vaginally.
Preeclampsia
- New-onset hypertension of >140/90 mmHg after 20 weeks and 1 of the following
- Proteinuria
- Other organ involvement (e.g. renal insufficiency (creatinine > or = 90 umol/L), liver, neurological, haematological, uteroplacental dysfunction)
Potential consequences of pre-eclampsia
eclampsia
other neurological complications include altered mental status, blindness, stroke, clonus, severe headaches or persistent visual scotomata
fetal complications
intrauterine growth retardation
prematurity
liver involvement (elevated transaminases)
haemorrhage: placental abruption, intra-abdominal, intra-cerebral
cardiac failure
Features of severe pre-eclampsia
hypertension: typically > 160/110 mmHg and proteinuria as above
proteinuria: dipstick ++/+++
headache
visual disturbance
papilloedema
RUQ/epigastric pain
hyperreflexia
platelet count < 100 * 106/l, abnormal liver enzymes or HELLP syndrome
Reducing the risk of hypertensive disorders in pregnancy
Women with the following should take aspirin 75-150 mg daily from 12 weeks gestation until the birth
≥ 1 high risk factors
≥ 2 moderate factors
High risk:
- hypertensive disease in a previous pregnancy
- chronic kidney disease
- autoimmune disease, such as systemic lupus erythematosus or antiphospholipid syndrome
- type 1 or type 2 diabetes
- chronic hypertension
Moderate risk:
- first pregnancy
- age 40 years or older
- pregnancy interval of more than 10 years
- body mass index (BMI) of 35 kg/m² or more at first visit
- family history of pre-eclampsia
multiple pregnancy
Preeclampsia assessment and management
Initial assessment
- NICE recommend arranging emergency secondary care assessment for any woman in whom pre-eclampsia is suspected
- Women with blood pressure ≥ 160/110 mmHg are likely to be admitted and observed
Further management
- oral labetalol is now first-line following the 2010 NICE guidelines.
- Nifedipine (e.g. if asthmatic) and hydralazine may also be used
Delivery of the baby is the most important and definitive management step. The timing depends on the individual clinical scenario
Group B Streptococcus
Group B Streptococcus (GBS) is the most common cause of early-onset severe infection in the neonatal period. It is thought around 20-40% of mothers have GBS present in their bowel flora and may therefore be thought of as ‘carriers’ of GBS. Infants may be exposed to maternal GBS during labour and subsequently develop potentially serious infections.
Risk factors for Group B Streptococcus (GBS) infection:
prematurity
prolonged rupture of the membranes
previous sibling GBS infection
maternal pyrexia e.g. secondary to chorioamnionitis
GBS
The Royal College of Obstetricians and Gynaecologists (RCOG) published guidelines on GBS in 2017.
The main points are as follows:
universal screening for GBS should not be offered to all women
the guidelines also state a maternal request is not an indication for screening
women who’ve had GBS detected in a previous pregnancy should be informed that their risk of maternal GBS carriage in this pregnancy is 50%. They should be offered intrapartum antibiotic prophylaxis (IAP) OR testing in late pregnancy and then antibiotics if still positive
if women are to have swabs for GBS this should be offered at 35-37 weeks or 3-5 weeks prior to the anticipated delivery date
IAP should be offered to women with a previous baby with early- or late-onset GBS disease
IAP should be offered to women in preterm labour regardless of their GBS status
women with a pyrexia during labour (>38ºC) should also be given IAP
benzylpenicillin is the antibiotic of choice for GBS prophylaxis
Uterine fibroids
Fibroids are benign smooth muscle tumours of the uterus. They are thought to occur in around 20% of white and around 50% of black women in the later reproductive years.
Associations
more common in Afro-Caribbean women
rare before puberty, develop in response to oestrogen
Features of uterine fibroids
may be asymptomatic
menorrhagia
may result in iron-deficiency anaemia
lower abdominal pain: cramping pains, often during menstruation
bloating
urinary symptoms, e.g. frequency, may occur with larger fibroids
subfertility
rare features:
polycythaemia secondary to autonomous production of erythropoietin
Diagnosis of fibroids
Transvaginal USS
Management of fibroids
Asymptomatic fibroids
no treatment is needed other than periodic review to monitor size and growth
Management of menorrhagia secondary to fibroids
levonorgestrel intrauterine system (LNG-IUS)
useful if the woman also requires contraception
cannot be used if there is distortion of the uterine cavity
NSAIDs e.g. mefenamic acid
tranexamic acid
combined oral contraceptive pill
oral progestogen
injectable progestogen
Treatment to shrink/remove fibroids
medical
GnRH agonists may reduce the size of the fibroid but are typically useful for short-term treatment
ulipristal acetate has been in the past but not currently due to concerns about rare but serious liver toxicity
surgical
myomectomy: this may be performed abdominally, laparoscopically or hysteroscopically
hysteroscopic endometrial ablation
hysterectomy
uterine artery embolization
Hormone replacement therapy (HRT)
Involves the use of a small dose of oestrogen (combined with a progestogen in women with a uterus) to help alleviate menopausal symptoms.
HRT side effects
nausea
breast tenderness
fluid retention and weight gain
Complications of HRT
increased risk of breast cancer
increased by the addition of a progestogen
in the Women’s Health Initiative (WHI) study there was a relative risk of 1.26 at 5 years of developing breast cancer
the increased risk relates to the duration of use
the risk of breast cancer begins to decline when HRT is stopped and by 5 years it reaches the same level as in women who have never taken HRT
increased risk of endometrial cancer
oestrogen by itself should not be given as HRT to women with a womb
reduced by the addition of a progestogen but not eliminated completely
the BNF states that the additional risk is eliminated if a progestogen is given continuously
increased risk of venous thromboembolism
increased by the addition of a progestogen
transdermal HRT does not appear to increase the risk of VTE
NICE state women requesting HRT who are at high risk for VTE should be referred to haematology before starting any treatment (even transdermal)
increased risk of stroke
increased risk of ischaemic heart disease if taken more than 10 years after menopause
Injectable contraceptives - Depo Provera
Depo Provera is the main injectable contraceptive used in the UK*. It contains medroxyprogesterone acetate 150mg. It is given via in intramuscular injection every 12 weeks. It can however be given up to 14 weeks after the last dose without the need for extra precautions**
The main method of action is by inhibiting ovulation. Secondary effects include cervical mucus thickening and endometrial thinning.
Disadvantages include the fact that the injection cannot be reversed once given. There is also a potential delayed return to fertility (maybe up to 12 months)
Adverse effects
irregular bleeding
weight gain
may potentially increased risk of osteoporosis: should only be used in adolescents if no other method of contraception is suitable
not quickly reversible and fertility may return after a varying time
Contraindications
breast cancer: current breast cancer is UKMEC 4, past breast cancer is UKMEC 3
Urinary incontinence
Urinary incontinence (UI) is a common problem, affecting around 4-5% of the population. It is more common in elderly females.
Risk factors advancing age previous pregnancy and childbirth high body mass index hysterectomy family history
Overactive bladder (OAB)/ Urge incontinence
- Frequency and urgency
- due to detrusor overactivity
Stress incontinence
- leaking small amounts when coughing or laughing
Mixed incontinence
Both urge and stress
overflow incontinence:
due to bladder outlet obstruction, e.g. due to prostate enlargement
functional incontinence
comorbid physical conditions impair the patient’s ability to get to a bathroom in time
causes include dementia, sedating medication and injury/illness resulting in decreased ambulation
Initial investigation
bladder diaries should be completed for a minimum of 3 days
vaginal examination to exclude pelvic organ prolapse and ability to initiate voluntary contraction of pelvic floor muscles (‘Kegel’ exercises)
urine dipstick and culture
urodynamic studies
Management depends on whether urge or stress UI is the predominant picture. If urge incontinence is predominant:
bladder retraining (lasts for a minimum of 6 weeks, the idea is to gradually increase the intervals between voiding)
bladder stabilising drugs: antimuscarinics are first-line
NICE recommend oxybutynin (immediate release), tolterodine (immediate release) or darifenacin (once daily preparation)
Immediate release oxybutynin should, however, be avoided in ‘frail older women’
mirabegron (a beta-3 agonist) may be useful if there is concern about anticholinergic side-effects in frail elderly patients
If stress incontinence is predominant:
pelvic floor muscle training
NICE recommend at least 8 contractions performed 3 times per day for a minimum of 3 months
surgical procedures: e.g. retropubic mid-urethral tape procedures
duloxetine may be offered to women if they decline surgical procedures
a combined noradrenaline and serotonin reuptake inhibitor
mechanism of action: increased synaptic concentration of noradrenaline and serotonin within the pudendal nerve → increased stimulation of urethral striated muscles within the sphincter → enhanced